2010/12/16

Benarin

Release form, composition and packing Benarin 

Nasal drops 0.05% as a clear, colorless or slightly yellowish liquid, allowed easy opalescence. 1 ml of budesonide 500 mcg. Other ingredients: propylene glycol, polyethylene 400, benzoic acid, succinic acid, Trilon B, thiourea, nipazol, purified water. Generic international name, recommended by WHO, the Russian Federation agreed to write the international name - budesonide.

Clinico-pharmacological group: SCS for intranasal use.

Pharmacological action

SCS for intranasal use. Has anti-inflammatory, antiallergic and immunosuppressive effect. Increases the production lipomodulina, an inhibitor of phospholipase A, inhibits the release of arachidonic acid. Warns edge aggregation of neutrophils, reduces inflammatory exudation and production of lymphokines, inhibits the migration of macrophages, reduces the intensity of infiltration and granulation formation of chemotactic substances. Reduces the swelling of the nasal mucosa, the production of mucus. Improves mucociliary transport. Well tolerated during prolonged therapy, has almost no systemic effects, has no mineralocorticoid activity.

Pharmacokinetics

Absorption, distribution and metabolism

In the application of nasal drops absorption of budesonide is low. Ranked in the gastrointestinal tract of budesonide (90%) subjected to the effect of "first passage" through the liver to form inactive metabolites. Bioavailability of 10% for that part of the drug, which came in the gastrointestinal tract. Cmax is reached 15-45 minutes after intranasal application, and is 0.01 mg / dL. Plasma protein binding - 88%.

Breeding

Has a high systemic clearance - 84 l / h. T1 / 2 - 2.8 hours out through the intestines as a metabolite - 10%, kidney - 70%.

Statement
seasonal allergic rhinitis;
perennial allergic rhinitis.

Dosing regimen

Benarin assign adults (patients older than 18 years). Single dose intranasal application depends on the severity of the disease and is 60-120 mg (2-3 drops in each nostril). The daily dose is selected individually according to the severity of rhinitis.

As a rule, enough 2 single doses per day. The duration of maintenance therapy is determined individually. The maximum single dose is 200 mcg (100 mcg in each nostril) and a maximum daily dose - 400 micrograms for a period not exceeding 3 months.

Side effect

Maybe: burning, irritation, nasal mucosa, sneezing, kandidomikoz.

Contraindications
fungal, bacterial and viral infections of the respiratory system;
pulmonary tuberculosis;
hypersensitivity to the drug.

Pregnancy and lactation

Health & Safety Benarina during pregnancy and lactation is not currently installed.

Cautions

Using the drug should be avoided from dripping into his eyes.

Overdose

Symptoms: prolonged use Benarina in high doses, as well as simultaneous administration of corticosteroids for systemic use may develop symptoms of hypercortisolism.

Treatment: the phasing out of the drug.

Drug Interactions

With the simultaneous application of phenobarbital, phenytoin, rifampin reduce the effectiveness of budesonide (due to induction of enzymes of microsomal oxidation). Methandrostenolone and estrogens enhance the effect of budesonide.

Conditions and terms of

The drug should be stored in a dry place, protected from light and away from children at or above 25 ° C. Shelf life - 2 years.